Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment

Richard H. Haubrich, Sharon A. Riddler, A. Gregory Dirienzo, Lauren Komarow, William G. Powderly, Karin Klingman, Kevin W. Garren, David L. Butcher, James F. Rooney, David W. Haas, John W. Mellors, Diane V. Havlir

Research output: Contribution to journalArticlepeer-review

111 Scopus citations


BACKGROUND:: The metabolic effects of initial therapy for HIV-1 infection are important determinants of regimen selection. METHODS:: Open-label study in 753 subjects randomized equally to efavirenz or lopinavir/ritonavir(r) plus two nucleoside reverse-transcriptase inhibitor (NRTI) vs. the NRTI-sparing regimen of lopinavir/r plus efavirenz. Zidovudine, stavudine, or tenofovir with lamivudine was selected prior to randomization. Metabolic outcomes through 96 weeks were lipoatrophy, defined as at least 20% loss in extremity fat, and fasting serum lipids. RESULTS:: Lipoatrophy by dual-energy X-ray absorptiometry at week 96 occurred in 32% [95% confidence interval (CI) 25-39%] of subjects in the efavirenz plus two NRTIs arm, 17% (95% CI 12-24) in the lopinavir/r plus two NRTIs arm, and 9% (95% CI 5-14) in the NRTI-sparing arm (P ≤ 0.023 for all comparisons). Varying the definition of lipoatrophy (≤10 to &*le;40% fat loss) and correction for baseline risk factors did not affect the significant difference in lipoatrophy between the NRTI-containing regimens. Lipoatrophy was most frequent with stavudine-containing regimens and least frequent with tenofovir-containing regimens (P < 0.001), which were not significantly different from the NRTI-sparing regimen. Total cholesterol increases at week 96 were greatest in the NRTI-sparing arm (median +57 mg/dl) compared with the other two arms (+32-33 mg/dl; P < 0.001). Use of lipid-lowering agents was more common (25 vs. 11-13%) in the NRTI-sparing arm. CONCLUSION:: Lipoatrophy was more frequent with efavirenz than lopinavir/r when combined with stavudine or zidovudine, and less frequent when either drug was combined with tenofovir. Lipoatrophy was least frequent with the NRTI-sparing regimen, but this benefit was offset by greater cholesterol elevations and the need for lipid-lowering agents.

Original languageEnglish
Pages (from-to)1109-1118
Number of pages10
Issue number9
StatePublished - Jun 1 2009


  • Antiretroviral therapy
  • Lipoatrophy
  • Metabolic complication
  • Nonnucleoside reverse-transcriptase inhibitor
  • Protease inhibitor
  • Treatment naive


Dive into the research topics of 'Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment'. Together they form a unique fingerprint.

Cite this